PIK3CA and cancer: While some clinical trials indicate that PTEN status is also associated with the benefit of Akt inhibition [215, 223], another study demonstrates that there is no difference in the sensitivity to capivasertib between PI3K/PTEN-altered and PI3K/PTEN non-altered cancer patients [209].